全文获取类型
收费全文 | 31188篇 |
免费 | 2072篇 |
国内免费 | 156篇 |
专业分类
耳鼻咽喉 | 275篇 |
儿科学 | 445篇 |
妇产科学 | 332篇 |
基础医学 | 4699篇 |
口腔科学 | 931篇 |
临床医学 | 3029篇 |
内科学 | 7427篇 |
皮肤病学 | 461篇 |
神经病学 | 3533篇 |
特种医学 | 1898篇 |
外科学 | 4222篇 |
综合类 | 182篇 |
一般理论 | 11篇 |
预防医学 | 1274篇 |
眼科学 | 600篇 |
药学 | 1830篇 |
中国医学 | 52篇 |
肿瘤学 | 2215篇 |
出版年
2023年 | 251篇 |
2022年 | 182篇 |
2021年 | 821篇 |
2020年 | 526篇 |
2019年 | 718篇 |
2018年 | 806篇 |
2017年 | 624篇 |
2016年 | 891篇 |
2015年 | 997篇 |
2014年 | 1264篇 |
2013年 | 1549篇 |
2012年 | 2534篇 |
2011年 | 2543篇 |
2010年 | 1521篇 |
2009年 | 1369篇 |
2008年 | 2245篇 |
2007年 | 2258篇 |
2006年 | 2163篇 |
2005年 | 2051篇 |
2004年 | 1772篇 |
2003年 | 1670篇 |
2002年 | 1556篇 |
2001年 | 278篇 |
2000年 | 214篇 |
1999年 | 287篇 |
1998年 | 310篇 |
1997年 | 224篇 |
1996年 | 170篇 |
1995年 | 155篇 |
1994年 | 126篇 |
1993年 | 90篇 |
1992年 | 73篇 |
1991年 | 80篇 |
1990年 | 61篇 |
1989年 | 77篇 |
1988年 | 46篇 |
1987年 | 47篇 |
1986年 | 45篇 |
1985年 | 36篇 |
1984年 | 54篇 |
1983年 | 65篇 |
1982年 | 46篇 |
1981年 | 41篇 |
1980年 | 38篇 |
1977年 | 26篇 |
1975年 | 26篇 |
1938年 | 24篇 |
1937年 | 30篇 |
1936年 | 25篇 |
1935年 | 35篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
991.
Gfroerer S Fiegel H Ramachandran P Rolle U Metzger R 《World journal of gastroenterology : WJG》2012,18(24):3099-3104
AIM: To investigate morphological changes of intestinal smooth muscle contractile fibres in small bowel atresia patients.METHODS: Resected small bowel specimens from small bowel atresia patients (n = 12) were divided into three sections (proximal, atretic and distal). Standard histology hematoxylin-eosin staining and enzyme immunohistochemistry was performed to visualize smooth muscle contractile markers α-smooth muscle actin (SMA) and desmin using conventional paraffin sections of the proximal and distal bowel. Small bowel from age-matched patients (n = 2) undergoing Meckel’s diverticulum resection served as controls.RESULTS: The smooth muscle coat in the proximal bowel of small bowel atresia patients was thickened compared with control tissue, but the distal bowel was unchanged. Expression of smooth muscle contractile fibres SMA and desmin within the proximal bowel was slightly reduced compared with the distal bowel and control tissue. There were no major differences in the architecture of the smooth muscle within the proximal bowel and the distal bowel. The proximal and distal bowel in small bowel atresia patients revealed only minimal differences regarding smooth muscle morphology and the presence of smooth muscle contractile filament markers.CONCLUSION: Changes in smooth muscle contractile filaments do not appear to play a major role in postoperative motility disorders in small bowel atresia. 相似文献
992.
993.
994.
LaRocque RC Rao SR Lee J Ansdell V Yates JA Schwartz BS Knouse M Cahill J Hagmann S Vinetz J Connor BA Goad JA Oladele A Alvarez S Stauffer W Walker P Kozarsky P Franco-Paredes C Dismukes R Rosen J Hynes NA Jacquerioz F McLellan S Hale D Sofarelli T Schoenfeld D Marano N Brunette G Jentes ES Yanni E Sotir MJ Ryan ET;Global TravEpiNet Consortium 《Clinical infectious diseases》2012,54(4):455-462
995.
996.
997.
Cappato R Smith WM Hood MA Crozier IG Jordaens L Spitzer SG Ardashev AV Boersma L Lupo P Grace AA Bardy GH 《Journal of interventional cardiac electrophysiology》2012,34(3):325-332
The recent introduction of subcutaneous implantable cardioverter defibrillator (S-ICD) has raised attention about the potential of this technology for clinical use in daily clinical practice. We review the methods and results of the four studies conducted in humans for approval of this innovative technology for daily practice. Two studies using a temporary S-ICD system (acute human studies) were conducted to search for an appropriate lead configuration and energy requirements. For this purpose, 4 S-ICD configurations were tested in 78 patients at the time of transvenous (TV)-ICD implantation. The optimal configuration was tested in 49 more patients to comparatively assess the subcutaneous defibrillation threshold (S-DFT) versus the standard TV-ICD. Long-term implants were evaluated in 55 patients using an implanted system (chronic human study). The acute humans studies led to an optimal S-ICD configuration comprising a parasternal electrode and left anterolateral thoracic pulse generator. Both configurations successfully terminated 98% of induced ventricular fibrillation (VF), but significantly higher energy levels were required with S-ICD than with TV-ICD systems (36.6?±?19.8 J vs. 11.1?±?8.5 J). In the chronic study, all 137 VF episodes induced at time of implant were detected with a 98% conversion rate. Two pocket infections and four lead revisions were required during 10?±?1 months of follow-up. During this period, survival was 98%, and 12 spontaneous ventricular tachyarrhythmias were detected and treated by the device. These data show that the S-ICD systems here consistently detected and converted VF induced at time of implant as well as sustained ventricular tachyarrhythmias occurring during follow-up (248). 相似文献
998.
999.
Macdougall IC Canaud B de Francisco AL Filippatos G Ponikowski P Silverberg D van Veldhuisen DJ Anker SD 《European journal of heart failure》2012,14(8):882-886
Growing awareness that heart failure, renal impairment, and anaemia are frequent co‐morbidities which can exacerbate one another in a vicious circle of clinical deterioration has led to the concept of the cardiorenal anaemia syndrome (CRAS). The role of iron deficiency within this complex interplay has been less well examined. Scrutiny of data from the recent FAIR‐HF trial raises a new hypothesis: is it time for ‘CRAS’ to be supplemented with new acronyms such as CRIDS (cardiorenal–iron deficiency syndrome) or even CRAIDS (cardiorenal–anaemia–iron deficiency syndrome)? Iron deficiency occurs frequently in heart failure patients with or without anaemia. It not only impairs oxygen transport through reduced erythropoiesis, but adversely affects oxidative metabolism, cellular energetics, and immune mechanisms, and the synthesis and degradation of complex molecules such as DNA. One large observational study in patients with heart failure found iron deficiency to be an independent predictor of death or urgent heart transplantation (hazard ratio 1.58, 95% confidence interval 1.14–2.17, P = 0.005). In the FAIR‐HF trial, i.v. iron therapy was associated with significant improvements in physical functioning in iron‐deficient patients with heart failure, even in non‐anaemic patients in whom haemoglobin levels did not change following i.v. iron administration. Key questions regarding the use of i.v. iron supplementation in the setting of heart failure merit exploration and could readily be answered by appropriately designed clinical trials. It is to be hoped that these important clinical trials are conducted, to permit a more subtle characterization of the patient's pathological condition and interventional requirements. 相似文献
1000.